Marker or filler forming fluid

ABSTRACT

A solution for forming a marker or filler mass for an intracorporeal site. The solution contains a polar, water soluble non-aqueous solvent such as dimethyl sulfoxide and a bioabsorbable, essentially water insoluble polymer such as polylactic acid, or copolymers of lactic acid and glycolic acid. The solution may be delivered to the biopsy site by a suitable syringe and delivery tube. The delivery tube is preferably provided with a releasable radiopaque element on the distal tip which can be released within the polymeric marker mass formed in the biopsy cavity.

FIELD OF THE INVENTION

This invention relates generally to the introduction of filler or markermaterial into a patient's body, and particularly to the filling of abiopsy site within a patient's body from which a biopsy specimen hasbeen taken with a mass of marker material.

BACKGROUND OF THE INVENTION

In diagnosing and treating certain medical conditions, it is oftendesirable to perform a biopsy, in which a specimen or sample of tissueis removed for pathological examination, tests and analysis. As isknown, obtaining a tissue sample by biopsy and the subsequentexamination are typically employed in the diagnosis of cancers and othermalignant tumors, or to confirm that a suspected lesion or tumor is notmalignant. The information obtained from these diagnostic tests and/orexaminations is frequently used to devise a plan for the appropriatesurgical procedure or other course of treatment. For example, breastbiopsies may be taken where a suspicious lump or swelling is noticed ina breast. Examination of tissue samples taken by biopsy is of particularsignificance in the diagnosis and treatment of breast cancer. In theensuing discussion, the biopsy and treatment site described willgenerally be the human breast, although the invention is suitable formarking biopsy sites in other parts of the human and other mammalianbody as well.

After the biopsy sample is taken, it may take several days or weeksbefore the results of the examination of the sample are obtained, andstill longer before an appropriate treatment decision is reached. If thedecision involves surgery it is clearly important for the surgeon tofind the location in the breast from where the tumor tissue has beentaken in the biopsy procedure, so that the entire tumor and possiblysurrounding healthy tissue can be removed.

However, radiographically visible tissue features, originally observedin a mammogram, may be removed, altered or obscured by the biopsyprocedure. In order for the surgeon or radiation oncologist to directsurgical or radiation treatment to the precise location of the breastlesion several days or weeks after the biopsy procedure was performed,it is desirable that a biopsy site marker be placed in or on thepatient's body to serve as a landmark for subsequent location of thelesion.

Various types of biopsy site markers have been described, includingvisible markers applied externally to the patient's skin,radiographically (X-ray)-detectable tissue markers such as clips andstaples, and ultrasound-detectable markers, have also been described.X-ray-detectable marker wires may be inserted through a biopsy needle,leading from the surface of the patient's body to the biopsy site. Somemarkers may be biodegradable.

However, due to the consistency of breast tissue and the fact that thesebiopsy site markers are typically introduced while the breast is stillcompressed between the mammography plates, prior art biopsy markers maynot remain at the specific biopsy location after the breast has beendecompressed and removed from the mammography apparatus, and may sufferfrom additional disadvantages as well. In order to locate anX-ray-detectable marker left at a biopsy site, an additional mammographyis generally required at the time of follow up treatment or surgery. Inaddition, once it is located using mammography, the biopsy site mustusually be marked again with a location wire that is visible by eye toprovide guidance to the clinician performing the treatment or surgery.However, as the patient is removed from the mammography apparatus, orotherwise transported, the position of the location wire can change orshift before the treatment or surgery is performed, which may result intreatments being misdirected to undesired locations. Furthermore, atleast some prior art biopsy site markers can remain present at the siteof implantation for an indefinite period of time and, if not surgicallyremoved, may obscure or otherwise interfere with any subsequentmammography or imaging studies.

However, due to the large amount of fibrous tissue normally present in ahuman breast, and due to the presence of ligaments running through thebreast, a marker that simply has a bright signal alone will not providea useful signal that is readily discernable from the many anatomicfeatures normally present within a human breast. Such markers aretypically small, being sized to fit within a syringe or other deliverytube, and so are often not readily distinguishable from natural featuresof the breast, which include occasional small ultrasound-bright spots.

As an alternative or adjunct to radiographic imaging, ultrasonic imagingand visualization techniques (abbreviated as “USI”) can be used to imagethe tissue of interest at the site of interest during a surgical orbiopsy procedure or follow-up procedure. USI is capable of providingprecise location and imaging of suspicious tissue, surrounding tissueand biopsy instruments within the patient's body during a procedure.Such imaging facilitates accurate and controllable removal or samplingof the suspicious tissue so as to minimize trauma to surrounding healthytissue.

For example, during a breast biopsy procedure, the biopsy device isoften imaged with USI while the device is being inserted into thepatient's breast and activated to remove a sample of suspicious breasttissue. As USI is often used to image tissue during follow-up treatment,it may be desirable to have a marker, similar to the radiographicmarkers discussed above, which can be placed in a patient's body at thesite of a surgical procedure and which are visible using USI. However,radiopaque markers may not be visible with USI. A marker visible withUSI enables a follow-up procedure to be performed without the need fortraditional radiographic mammography imaging which, as discussed above,can be subject to inaccuracies as a result of shifting of the locationwire as well as being tedious and uncomfortable for the patient.

Thus, there is need in the art for biopsy site markers that aredeliverable into the cavity created by removal of the biopsy specimenand not into tissue that is located outside of that biopsy cavity, andwhich will not migrate from the biopsy cavity even when the breasttissue is moved, manipulated or decompressed. Moreover, such desiredmarkers should remain detectable at the biopsy site (i.e., within thebiopsy cavity for a desired time period); should not interfere withimaging of the biopsy site and adjacent tissues at a later time; andshould be readily distinguishable in the various imaging procedures fromlines of calcifications which frequently are signs for a developingmalignancy.

SUMMARY OF INVENTION

The invention is directed to the deployment of a marker or fillerforming material at intracorporeal locations such as biopsy sites, sitesfor cosmetic treatments and other sites which may need additional bulk.The marker or filler material is formed intracorporeally from abiocompatible solution having as a solute bioabsorbable polymericmaterial which is relatively insoluble in body fluid or other waterbased fluids and a water soluble, non-aqueous polar solvent such asdimethyl sulfoxide (DMSO). Suitable bioaborbable polymers includepolylactic acid, polyglycolic acid, polycaprolactones and copolymers andblends thereof. When the marker or filler forming fluid contacts bodyfluid or other water based fluids present at intracorporeal locations,the non-aqueous solvent is quickly absorbed by the body fluid or waterbased fluid present at the site, precipitating a mass of the waterinsoluble bioabsorbable polymeric material at the site. The polymericmaterial forming the marker or filler mass is preferably inherentlyultrasonically detectable or the marker fluid may be treated to have aplurality of gas bubbles or otherwise aerated, so that upon formation ofthe polymeric mass at the site, gas is incorporated in the solid massforming to provide ultrasonically detectable porosity.

The following description of embodiments of the invention is primarilydirected to deployment of mass at a biopsy site for purposes of remotedetection of the biopsy site. However, it should be recognized that theinvention may be employed to form filling or bulking masses at anintracorporeal locations for cosmetic and other uses, as previouslyalluded to.

After a biopsy specimen is removed from the patient, a guiding membersuch as a cannula or other tubular member is preferably left within thepatient with the distal end thereof within or close to the biopsy sitein order to provide subsequent access to the biopsy site. The tubularguiding member may be part of the biopsy system such as a SenoCor 360™or a Mammotome® system which was used to separate the tissue specimenand remove it from the site but which remains in place after thespecimen has been removed. The marker forming fluid embodying featuresof the invention, may be suitably delivered by a syringe with anelongated delivery tube which at least in part fits within a tubularguiding member leading to the biopsy site.

Generally, the amount of polymeric solute ranges from about 1 to about50%, preferably about 10 to about 35% by weight of the marker or fillerforming fluid. The ratio of the polymer solute to the solvent can bevaried to adjust the delivery characteristics and the in-vivo lifetime(i.e. the time period in which the polymeric mass is at the biopsysite). For example a lower percentage of polymeric material in the mixwill provide a softer or more friable marker mass within the cavity,whereas a higher percentage will provide a firmer marker mass. Lowerpercentages of solvent will provide thicker marker fluids which will notbe readily displaced from the biopsy site, whereas higher percentageswill provide a less viscous solution which is easier to deliver. Highmolecular weight polylactic acid provides a longer in-vivo life time,e.g. up to a year or more. A lower molecular weight polymeric materialsuch as a copolymer of lactic acid (90%) and glycolic acid (10%)provides an in-vivo life time of about two to three weeks. A copolymerof lactic acid (65%) and glycolic acid (35%) with a molecular weight ofabout 60 kD has an in-vivo lifetime of about 12 to 14 weeks.

An ultrasound-detectable marker typically must remain in place and beremotely detectable within a patient for at least 2 weeks to have anypractical clinical value. Thus, an ultrasound-detectable marker materialembodying features of the invention is detectable at a biopsy sitewithin a patient for a time period of at least 2 weeks, preferably atleast about 6 weeks, and may remain detectable for a time period of upto about 20 weeks or more. An ultrasound-detectable marker massembodying features of the invention is preferably not detectable afterabout one year, and usually not more than about 6 months after placementat a biopsy site. More preferably, the ultrasound-detectable marker massshould not be detectable with ultrasound after about 12 weeks fromplacement at a biopsy site. A preferable in-vivo lifetime for anultrasound-detectable biopsy marker mass having features of theinvention is about 6 weeks to about 12 weeks.

The detectable marker mass which forms in the biopsy cavity should belarge enough to fill a substantial portion, preferably all of thecavity. This allows the detection and definition of the boundaries ofthe biopsy cavity. The accessing passageway leading to the biopsy cavitymay also at least in part be filled with the marker fluid as well ifdesired, which allows the physician to follow to locate the marker mass.The marker mass which forms in the cavity is ultrasonically detectable,but the marker fluid may also include ultrasonically or radiographicallydetectable powders or other particulate to augment the detection of thepolymeric mass or the biopsy cavity. Other therapeutic and diagnosticagents may be incorporated into the marker fluid such as pharmaceuticalagents, chemotherapeutic agents, anesthetic agents, hemostatic agents,pigments, dyes, radiopaque agents, materials detectable by magneticresonance imaging (MRI), inert materials, and other compounds.

In one embodiment of the invention, the delivery system is employed toincorporate a radiopaque or other type of long term or permanent markerelement within the polymeric mass which forms in the biopsy cavity. Forexample, the distal end of the syringe assembly or the tubular guidemember leading to the biopsy site may be provided with a distal tipwhich is formed of radiopaque or other suitable material and which isreleasably secured to the distal portion of the syringe or guide memberso that upon formation of the marker mass from the marker fluid, thedistal tip of the syringe or guide member can be released within theformed polymer marker mass and the syringe or guide member then removedfrom the mass.

The biopsy site markers formed by the present invention provideultrasonically bright images which can be readily distinguished from theultrasound signals arising naturally from within a breast or othertissue and which readily contrasts with the dark ultrasound shadowregion immediately behind the bright ultrasound echo region. Thestrength of the reflected signal, and the contrast with the shadowregion, make the marked site readily detectable even to relativelyinexperienced surgeons. The in-vivo lifetime of the marker at the biopsysite can be preselected by adjusting the amount of polymeric material inthe marker fluid and the molecular weight thereof. The employment of thefiller forming functions of the solution may be advantageously utilizedin cosmetic treatments similar to the uses of collagen, e.g. wrinkleremoval or minimization, or in situations in which additional bulk isneeded within a patient's body, e.g., treating for urinary incontinence.

These and other advantages will be evident from the following detaileddescription when taken in conjunction with the accompanying exemplarydrawings.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A is an elevational view, partially in section, of a marker fluiddelivery system embodying features of the invention.

FIG. 1B is a transverse cross-sectional view taken along line 1B-1Bshown in FIG. 1A.

FIG. 1C is a transverse cross-sectional view taken along line 1C-1Cshown in FIG. 1A.

FIG. 1D is a transverse cross-sectional view taken along line 1D-1Dshown in FIG. 1A.

FIG. 2 is a partially cut-away, perspective view of a system asillustrated in FIG. 1 shown depositing a marker fluid embodying featuresof the invention at a biopsy site within a breast of a female patient.

FIG. 3 is a perspective view, partially in section, of the distalportion of a delivery system having a releasable marker element on thedistal tip of the delivery tube which acts as a long term or permanentmarker.

FIG. 4 is a longitudinal, centerline cross-section of a delivery systemhaving a releasable radiopaque distal tip.

FIG. 5 is a longitudinal, centerline cross-section of a delivery systemhaving a releasable radiopaque distal tip which is threadably connectedto the distal end of the delivery cannula and which has a groovedexterior to facilitate release of the distal tip.

FIG. 6 is a transverse cross-sectional view of the releasable distal tipshown in FIG. 5 taken along the lines 6-6.

FIG. 7 is an elevational view of a delivery cannula suitable for use todeliver the marker or filler forming fluid embodying features of theinvention.

DETAILED DESCRIPTION OF THE INVENTION

FIGS. 1A-1D illustrate a system 10 for delivery of biopsy marker fluid11 embodying features of the invention to a biopsy site within apatient's body. The system 10 includes a syringe 12 having a bore 13containing a quantity of biopsy marker fluid 11. A plunger 14 with asealable distal end 15 is slidably disposed within the bore 13 ofsyringe 12. Application of pressure to the head 16 of plunger 14 appliespressure to the fluid 11 and causes the discharge of fluid 11 from thebore 13 into the inner lumen 17 of delivery tube 18 secured to thedischarge end of syringe 12. The marker fluid 11 passes through theinner lumen or bore 17 of the delivery tube 18 and out the dischargeport 19 in the distal end of delivery tube 18.

As schematically illustrated in FIG. 1A, delivery tube 18 is secured tothe syringe 12 by a friction fit. However, those skilled in the art willrecognize that a variety of connections may be made between the syringe12 and the delivery tube 18 such as a conventional luer-lock. Thedelivery tube 18 may have markings, such as lines or dots spaced atregular intervals along the length of the tube to indicate its positionwithin the patient.

FIG. 2 illustrates the marker fluid delivery system 10 shown in FIGS.1A-1D with the distal portion of the delivery tube 18 operativelydisposed within a patient's breast 20 with the distal tip 21 of thedelivery tube 18 disposed within biopsy cavity 22 at the biopsy site 23ready to deliver marker fluid 11. An incision 24 in the breast 20 allowsaccess to the cavity 22. Biopsy tubular guide member 25 extends throughincision 24 in the patient's breast 20 into cavity 22 at biopsy site 23.The distal end 26 of syringe 12, containing marker fluid 11, is tightlyengaged with delivery tube 18, which extends within guide member 25 soas to locate delivery tube outlet port 19 within biopsy cavity 22. Theouter diameter of the delivery tube 18 is configured to allow thedelivery tube to slidably fit inside the inner lumen 27 of biopsy guidemember 25. Markings 28 spaced at regular intervals along the outersurface of delivery tube 18 indicate the depth of insertion of the tubewithin the guide member 25 and aid in the proper placement of dischargeport 19 into position within cavity 22. Depression of plunger 14 of thesyringe 12 forces marker fluid 11 out of syringe 12 through the innerlumen 17 of the delivery tube 18 and out port 19 into the cavity 22.

Fluid 11 mixes with body fluid or other water based fluid which may bepresent in the cavity 22. The solvent in fluid 11 is quickly dissolvedin the body fluid or other water based fluid. The polymer solute whichprecipitates is relatively insoluble in the body fluid or other waterbased fluid which may be present in the cavity and forms a porous,ultrasonically detectable and bioabsorbable polymer mass (not shown)within the cavity 22. The polymer mass preferably essentially fills thebiopsy cavity 22 so as to define the periphery of the biopsy cavity andto ensure that the mass remains within the biopsy cavity and will notmigrate. The mass is subsequently absorbed by tissue and fluids near thebiopsy site, so that at the end of the in-vivo life time of thebioabsorbable mass, the marker mass is no longer readily detectable atthe site by ultrasonic means. Tissue ingrowth usually replaces theabsorbed mass.

The preferred solvent for the fluid 11 is a pharmaceutical grade (USP)of DSMO. Other biocompatible water soluble, polar solvents are suitable.The preferred relatively water-insoluble bioabsorbable polymers arepolylactic acid, poly glycolic acid, copolymers of lactic acid andglycolic acid, polycaprolactone. However, other suitable bioabsorbable,essentially water insoluble polymers include poly(esters), poly(hydroxyacids), poly(lactones), poly(amides), poly(ester-amides), poly(aminoacids), poly(anhydrides), poly(ortho-esters), poly(carbonates),poly(phosphazines), poly(thioesters), poly(urethanes), poly(esterurethanes), polysaccharides, polylactic acid, polyglycolic acid,polycaproic acid, polybutyric acid, polyvaleric acid, and copolymers,polymer alloys, polymer mixtures, and combinations thereof.

The marker mass preferably essentially fills the biopsy cavity so as todefine the periphery of the biopsy site cavity and to ensure that themarker mass remains within the biopsy cavity and will not migrate. Themarker materials are resorbed by tissue and fluids near the biopsy site,so that, after their in-vivo life times, the marker materials are nolonger USI-detectable at the biopsy site.

The marker fluid may also include radiopaque materials or radiopaquemarkers, so that the biopsy site may be detected both with ultrasoundand with X-ray or other radiographic imaging techniques. Radiopaquematerials and markers may include metal objects such as clips, bands,strips, coils, and other objects made from radiopaque metals and metalalloys, and may also include powders or particulate masses of radiopaquematerials. Radiopaque markers may include liquid contrast agents such asEthiodol or other non-water based contrast agents. Radiopaque markersmay be of any suitable shape or size, and are typically formed in arecognizable shape not naturally found within a patient's body. Suitableradiopaque materials include stainless steel, platinum, gold, iridium,tantalum, tungsten, silver, rhodium, nickel, bismuth, other radiopaquemetals, alloys and oxides of these metals, barium salts, iodine salts,iodinated materials, and combinations of these. The marker fluid mayalso include MRI-detectable materials or markers, so that the biopsysite may be detected with MRI techniques. MRI contrast agents such asgadolinium and gadolinium compounds, for example, are suitable for usewith ultrasound-detectable biopsy marker materials embodying features ofthe invention. Colorants, such as dyes (e.g., methylene blue and carbonblack) and pigments (e.g., barium sulfate), may also be included in themarker fluid of the invention. The colorant such as carbon black usuallyremains in the track or passageway leading to the marker or filler massand this can be followed by the surgeon to the desired location.

Therapeutic agents to reduce bleeding, enhance clotting, to causevasoconstriction, to prevent infections and other diseases, to reducepain, chemotherapeutic agents to treat remnant cancer cells at the sitemay be incorporated into the marker fluid. Suitable therapeutic agentsare provided in co-pending application Ser. No. 10/124,757, filed Apr.16, 2002, which is incorporated herein in its entirety by reference.

FIGS. 3 and 4 depict the distal portion of an alternative delivery tube30 which is disposed within tubular guide 31 and which has a releasableradiopaque element 32 on the distal tip of the delivery tube. A cannula33 is slidably disposed about the delivery tube 30. Relativelongitudinal movement between the cannula 33 and delivery tube 30, asdepicted by arrows 34 and 35, pushes the radiopaque element 32 off theend of the tube into the cavity 36 as shown in FIG. 4. When the markerfluid 37 containing a non-aqueous, water soluble solvent and arelatively water insoluble polymeric solute is injected into the biopsycavity 36 and the polymer mass is formed, the radiopaque element 32 isreleased from the delivery tube 30 and left within the polymer mass. Theradiopaque element 32 is released within the polymer mass at a point inthe formation of the mass which ensures that the position of theradiopaque element 32 is maintained after the distal end of the deliverytube 30 is removed from the cavity 36. Preferably, the radiopaqueelement 32 is centrally located within the biopsy cavity 36.

FIGS. 5 and 6 illustrate an alternative embodiment in which a releasableradiopaque element 40 is the distal tip of delivery tube 41. As shown,the element 40 is threadably connected to the distal portion of thedelivery tube 41 and has a grooved exterior 42 which helps to fix thetip in the polymeric mass. This allows the delivery tube 41 to beunscrewed from the tip element 40 and to be withdrawn from the patient,leaving the radiopaque tip 40 within the polymeric mass.

The releasable radiopaque element may have a variety of other shapeswhich are recognizable as not being naturally found within a patient'sbody to facilitate remote detection radiographically or ultrasonically.For example, the radiopaque may have an exterior transverse shape suchas a star or a square. The radiographically detectable distal tip may beformed of a suitable radiopaque material such as stainless steel,platinum, gold, iridium, tantalum, tungsten, silver, rhodium, nickel,bismuth, other radiopaque metals, alloys and oxides of these metals.Radiopaque salts such as barium salts, iodine salts, iodinatedmaterials, and combinations of these may be incorporated into polymericor ceramic materials which form the releasable tip.

As shown in FIG. 7, the deployment system may have a delivery tube 50with a needle-like distal tip 51 to facilitate advancement of thedelivery tube through tissue to the target site. This embodiment isparticularly suitable in those situations in which there is no guidetube or other cannula in place to provide access to the target site.

Markers embodying features of the present invention remain detectable atan intracorporeal site for a desired time period, and degrade ordissolve so as to not interfere with imaging of the biopsy site andadjacent tissues at a later time. Suitable marker materials typically donot migrate from the biopsy site before being dissolved or otherwiseabsorbed, and so provide reliable temporary marking of the location of abiopsy site and the margins thereof. The marker materials havingfeatures of the invention are readily distinguishable from natural bodyfeatures including signs of a developing or an actual malignancy. Thepresent invention also includes apparatus and method for deliveringmarkers to a biopsy site.

The purpose of markers embodying features of the invention is tofacilitate the location and performance of a surgical procedure that isperformed while the marker is still detectable. The in-vivo lifetime ofthe marker mass remaining in the biopsy cavity is relatively short, e.g.less than one year, preferably less than about six months. Typically,the marker mass should have an in-vivo life time of about 6 to about 20weeks, preferably 6 to 12 weeks. The disappearance of a marker after alonger period of time is required to avoid obscuring or interfering withfollow-up imaging or further mammography.

Typically, the marker fluid embodying features of the present inventioncontaining ultrasound-detectable solute of bioabsorbable polymericmaterial of the present invention is deposited at a biopsy site within apatient's body to form a biopsy marker mass at the site to allow for thesubsequent location of the site by medical personnel. Thus, for example,a quantity of fluid formed of a non-aqueous water soluble solvent suchas DSMO with a bioabsorbable polymeric material which is essentiallyinsoluble in body fluids or other water based fluids is delivered into acavity at a biopsy site. When the solution comes into contact with bodyfluid or other water based fluid at the biopsy site, the solvent isquickly dissolved in the body fluid and the relatively water insolublepolymeric solute forms a marker mass within the biopsy cavity.

The in-vivo lifetime of the polymeric material, i.e. the time period inwhich the polymeric mass is ultrasonically detectable, is related to themolecular weight of the polymer. For example, copolymers of lactic andglycolic acids having an initial molecular weight of about 45,000Daltons (45 kD) before processing, are suitable for use in making anultrasound-detectable marker material having an in-vivo lifetime ofabout 12 weeks. As is known to those of ordinary skill in the art, othermaterials, including other polymeric materials, may require a differentstarting molecular weight in order to obtain the same in-vivo lifetime.For example, polyglycolic acid typically degrades faster than othermaterials and as such requires a substantially higher initial molecularweight than polylactic acid or polycaprolactone to obtain a similarin-vivo lifetime.

Many properties of a material affects the intensity of its ultrasoundreflection, including density, physical structure, molecular material,and shape. For example, sharp edges, or multiple reflecting surfaces onor within an object differing in density from its surroundings enhancesits ability to be detected by ultrasound. Interfaces separatingmaterials of different densities, such as between a solid and a gas,produce strong ultrasound signals.

The methods of the present invention provide materials having a porosityeffective to produce strong ultrasound signals when located within thepatient's biopsy cavity. The polymeric material may naturally form aporous mass or porosity can be formed by introducing a gas into thematerial during processing of a material, by release of gas from withinthe material, or by directing a gas into a material or by incorporatinga blowing agent.

A typical human breast has a substantial number of features that arevisualized with ultrasound. These features all have characteristicsignals. Fibrous tissue or ligaments tend to show up as bright streaks,fat seems to appear as a dark gray area, the glandular tissue appears asa mottled medium gray mass. Cancerous lesions typically appear as adarker area with a rough outer edge which has reduced throughtransmission of the ultrasound energy. One advantage of theultrasound-detectable biopsy marker materials of the present inventionis that the materials provide an ultrasound signal which can be readilydifferentiated from anatomic structures within the breast, so that theidentification and marking of a biopsy cavity does not require extensivetraining and experience.

The delivery syringe and the delivery tube attached to the syringe maybe sized to accept any volume of marker or filler forming fluid desiredto be injected into the desired intracorporeal site. The averageMammotome® biopsy removes about 0.5 to about 2, typically about 1 ml oftissue. The volume of marker fluid introduced into the biopsy cavitywhich remains after the removal of the tissue specimen is about the sameas the tissue volume removed. Use of more marker fluid typically leadsto some filling of the accessing passageway as well as of the cavity atthe biopsy site. Smaller volumes of marker fluid may be used for smallercavities at a biopsy site, such as are created with a single SenoCor360™ biopsy or an automated Tru-Cute® biopsy.

The solution embodying features of the invention may also be employed asa filler or bulking agent. For example, the filler forming fluid may beused in a manner similar to collagen for cosmetic purposes to minimizewrinkles, to fill pockmarks and other surface pits. The solution mayalso be used to bulk up an area of tissue for a variety of reasons. Forexample, if a radiation source for treating a tumor or a tumor siteafter removal of the tumor is located too close to the patient's skin,e.g. less than about 5 mm, the skin may be damaged or ultimately scarredby the irradiation. By deploying the filler forming fluid embodyingfeatures of the invention between the irradiation source and the skin,the damage or scarring to the skin can be reduced or eliminated.Depending upon the source of the radiation, either a single bolus ormultiple bolus may be employed to bulk up the region and to displace theskin sufficiently to avoid damage.

The filler forming fluid embodying features of the invention may also beemployed to provide a bulking mass about a urethra in the treatment ofurinary incontinence, for a bulking mass about an anal sphincter forfecal incontinence and a bulking mass about an esophageal sphincter forgastroesophageal reflux disease. Other uses will become apparent tothose skilled in the art.

While particular forms of the invention have been illustrated anddescribed, it will be apparent that various modifications can be madewithout departing from the spirit and scope of the invention.Accordingly, it is not intended that the invention be limited to thespecific embodiments illustrated and shall be defined by the scope ofthe appended claims as broadly as the prior art will permit. Moreover,those skilled in the art will recognize that features shown in oneembodiment may be utilized in other embodiments. Terms such a “element”,“member”, “device”, “sections”, “portion”, “section”, “steps” and wordsof similar import when used herein shall not be construed as invokingthe provisions of 35 U.S.C. §112(6) unless the following claimsexpressly use the terms “means” or “step” followed by a particularfunction without specific structure or action.

1. A system for at least partially filling and marking a cavity at asite within a patient's breast from which tissue has been removed,comprising: a. a syringe having an elongated body, an inner bore, aplunger slidably disposed within the inner bore; b. a delivery tubehaving a distal end with a discharge port and a bore in fluidcommunication with the inner bore of the syringe and the discharge port;c. a quantity of marker forming fluid within the bore of the syringeconfigured to at least partially fill the cavity at the biopsy site andform therein a porous bioabsorbable body, the marker forming fluidcomprising a non-aqueous solvent which is relatively soluble in a bodyfluid or other water based fluid, a bioabsorbable polymeric solutecomprising a copolymer of polylactic acid and polyglycolic acid in aweight ratio of 90:10 to 60:40 in the non-aqueous solvent which isrelatively insoluble in body fluid or other water based fluid and whichforms in the cavity the porous bioabsorbable body; and d. a releasable,remotely detectable distal tip at the distal end of the delivery tubecomprising radiopaque metal and configured to remain within the porousbody within the cavity upon the formation thereof, wherein thereleasable, remotely detectable radiopaque distal tip at the distal endof the delivery tube defines the discharge port.
 2. The system of claim1, wherein the quantity of marker forming fluid in the inner bore of thesyringe is about 0.2 ml to about 1.2 ml.
 3. The system of claim 1,wherein the radiopaque part of the releasable distal tip is formed ofone or more materials selected from the group consisting of stainlesssteel, platinum, gold, iridium, tantalum, tungsten, silver, rhodium,nickel, bismuth, other radiopaque metals, alloys of radiopaque metalsand mixtures of radiopaque metals, and combinations thereof.
 4. Thesystem of claim 1, wherein the marker forming fluid includes at leastone agent selected from the group consisting of therapeutic ordiagnostic agents.
 5. The system of claim 4, wherein the agent is ahemostatic agent.
 6. The system of claim 1, wherein the marker formingfluid includes a radioactive element.
 7. The system of claim 6, whereinthe radioactive element is a brachytherapy seed.
 8. The system of claim1, wherein the copolymer comprises about 65% (by wt.) polylactic acidand about 35% (by wt.) polyglycolic acid.
 9. The system of claim 1,wherein the marker forming fluid contains about 1 to about 50% by weightwater insoluble, bioabsorbable polymeric solute.
 10. The system of claim1, wherein the marker forming fluid contains about 10 to about 90% byweight water insoluble, bioabsorbable polymeric solute.
 11. The systemof claim 1, wherein the marker forming fluid is dimethyl sulfoxide.